



Australian Government

Department of Health, Disability and Ageing

Therapeutic Goods Administration

FOI 26-2560

Branch/Section: AEMDS/PBFT

Scope of the request:

5. Document that contains the total number of adverse events reported to the TGA associated with the prescription of 3,4-Methylenedioxymethamphetamine (MDMA) under the Authorised Prescriber scheme since July 2023
6. Document that contains the total number of adverse events reported to the TGA associated with the prescription of psilocybin under the Authorised Prescriber scheme since July 2023.

The timeframe for this request is from 7 July 2023 to 31 December 2025.

Name of the Medicine	Total number of adverse events reported to TGA
3,4 - Methylenedioxymethamphetamine (MDMA)	0
Psilocybin	0

Product Profile	Count of Prescribers
3,4-Methylenedioxymethamphetamine (MDMA)	48
Psilocybine	40

Product Profile	Sum of Patients Reported
3,4-Methylenedioxymethamphetamine (MDMA)	123
Psilocybine	65